We are live on ! Find out more
BNGO icon

Bionano Genomics

32 hedge funds and large institutions have $1.35M invested in Bionano Genomics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more capital invested

Capital invested by funds: $417K → $1.35M (+$937K)

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

6.19% more ownership

Funds ownership: 2.51%8.7% (+6.2%)

0% more funds holding

Funds holding: 3232 (0)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

Holders
32
Holders Change
Holders Change %
0%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
5
Reduced
8
Closed
8
Calls
Puts
Net Calls
Net Calls Change

BNGO Hedge Fund Activity: Q4 2025 in Review

32 of the 8,239 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q4 2025, worth a combined $1.35M — up 225% from $417K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new BNGO positions and 8 closed out — a net gain of 1 holder — while 5 added to existing stakes and 8 trimmed.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $585K. The largest seller was UBS Group, cutting an estimated $94.9K.

  • 32 institutional investors held Bionano Genomics (BNGO) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $1.35M of Bionano Genomics stock for Q4 2025, up 225% quarter-over-quarter.
  • 9 funds opened new Bionano Genomics positions in Q4 2025 and 8 closed out, a net change of +1 holder.
  • The largest Bionano Genomics buyer in Q4 2025 was GSA Capital Partners, an estimated $585K added.
  • The largest Bionano Genomics seller in Q4 2025 was UBS Group, an estimated $94.9K sold.

Based on aggregated 13F filings for Q4 2025.